[Media Releases] [Inews] NeoPharm and LegoChem co-develop a novel anti-inflammary drug

Title: NeoPharm and LegoChem co-develop a novel anti-inflammary drug

Publication: inews / Hye Jeong Lim

Date: 21 June 2007

Summary 

• NeoPharm and LegoChem signed an agreement on co-developing new PAR2 inhibitors.                                                      

• NeoPharm is investing $0.5 milion in LegoChem, acquiring 3.46% of the equity, and is entitled to receive certain portion of royalties.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).